1. Ford ES, Li C, Zhao G, et al. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Int Med. 2009;169(6):572–578.
2. Blaha M, Blumenthal R, Brinton E, Jacobson T. The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008;2(4):267–273.
3. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol. 1992;70(19):3H–9H.
4. Knopp RH, Paramsothy P, Atkinson B, Dowdy A. Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol. 2008;101(8A): 48B–57B.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285(19):2486–2497.
6. Henderson JT, Weisman CS. Women’s patterns of provider use across the lifespan and satisfaction with primary care coordination and com- prehensiveness. Med Care. 2005;43(8):826–833.
7. Packard CJ, Demant T, Stewart JP, et al. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions. J Lipid Res. 2000; 41:305–317.
8. Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205–246.
9. Lichtenstein AH. Thematic review series: patient-oriented research. Dietary fat, carbohydrate, and protein: effects on plasma lipoprotein patterns. J Lipid Res. 2006;47(8):1661–1667.
10. Rader D, Hobbs H. Chapter 350. Disorders of lipoprotein metabolism. In: Fauci A, Braunwald E, Kasper D, et al, eds. Harrison’s Principles of Internal Medicine. 